• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.

作者信息

Suo Xiaohui, Fang Zheng, Wang Dongmei, Zhao Liyun, Liu Jie, Li Hong, Ma Xiaojun, Zhang Congcong, Zhao Xuemei, Shi Rui, Wu Yan, Jiao Zongjiu, Song Jiaojie, Zhang Ling, Li Ling, Zhang Suping, Lu Xinxiao, Yuan Linyu, Gao Sifeng, Zhang Jilei, Liu Kaiqi, Zhao Xingli, Bai Guanchen, Mi Yingchang

机构信息

Department of Hematology, Handan Central Hospital, Handan, Hebei, China.

Department of Hematology, The Second People's Hospital of Guiyang, Guiyang, Guizhou, China.

出版信息

Hematol Oncol. 2024 Jul;42(4):e3296. doi: 10.1002/hon.3296.

DOI:10.1002/hon.3296
PMID:39041653
Abstract
摘要

相似文献

1
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.
Hematol Oncol. 2024 Jul;42(4):e3296. doi: 10.1002/hon.3296.
2
Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.孕期难治性急性髓系白血病采用维奈克拉、大剂量阿糖胞苷和米托蒽醌治疗。
Br J Haematol. 2021 Jan;192(2):e60-e63. doi: 10.1111/bjh.17220. Epub 2020 Nov 21.
3
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
4
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.低强度CPX-351联合维奈克拉诱导治疗新诊断的不适合强化化疗的成年急性髓系白血病患者。
Blood Adv. 2024 Dec 24;8(24):6248-6256. doi: 10.1182/bloodadvances.2024013687.
5
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).接受去甲基化药物联合维奈克拉（HMA-Ven）或脂质体柔红霉素-阿糖胞苷（CPX-351）治疗的继发性急性髓系白血病的治疗结果
Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8.
6
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.维奈托克单药治疗后慢性淋巴细胞白血病和继发性急性髓系白血病的双重缓解：病例报告。
Medicine (Baltimore). 2021 Feb 12;100(6):e24703. doi: 10.1097/MD.0000000000024703.
7
Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study.维奈托克联合柔红霉素和阿糖胞苷治疗新诊断的急性髓系白血病：1b期研究结果
Blood. 2025 Apr 24;145(17):1870-1875. doi: 10.1182/blood.2024026700.
8
[Efficacy of venetoclax-based induction regimen in newly diagnosed pediatric acute myeloid leukemia].[维奈克拉为基础的诱导方案在新诊断儿童急性髓系白血病中的疗效]
Zhonghua Yi Xue Za Zhi. 2024 Jul 16;104(27):2513-2520. doi: 10.3760/cma.j.cn112137-20240108-00056.
9
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
10
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.维奈克拉联合阿糖胞苷和/或伊达比星治疗复发/难治性儿童急性髓系白血病的 1 期、剂量递增研究。
Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11.

引用本文的文献

1
Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control.工程化用于实体瘤的嵌合抗原受体T细胞：双特异性抗原靶向、肿瘤微环境调节和毒性控制。
Immunol Res. 2025 Sep 20;73(1):135. doi: 10.1007/s12026-025-09687-6.